Evidence map›Paper›PMID 39180470›Full record

ArticleJournal of veterinary pharmacology and therapeutics2025

Analysis of US Marketed Artemisinin Supplements for Use in Dogs.

Alyssa R Berman, Adam J Birkenheuer, Emily L Sorah, Mark G Papich

Abstract read
In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. StandardizedVeterinary sciences · 2025
    Article
  2. The Beneficial Use ofAnimals : an open access journal from MDPI · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alyssa R BermanDepartment of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.ORCID https://orcid.org/0009-0008-7837-5677
Adam J BirkenheuerDepartment of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-2617-2252
Emily L SorahVeterinary Hospital Pharmacy, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-2583-8120
Mark G PapichDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-7591-7898

Funding

Clinical Pharmacology Laboratory at the NC State College of Veterinary MedicineSalary Support for Dr. Berman via Merck Animal Health
6 · The paper itself

Abstract

Oral artemisinin has antiparasitic activity and may help improve treatment success rates in dogs infected with Babesia gibsoni. However, these artemisinin products are unapproved and unregulated botanical supplements. They have not been evaluated for safety and efficacy or for strength, purity, or quality compared with a reference standard. Before considering these products for a clinical study, we evaluated the strength of four suppliers of artemisinin capsules using an high-performance liquid chromatography method validated in our laboratory. We found that the four artemisinin-labeled products that were tested had high within product and between product variability in capsule strength compared with the stated capsule strength on the product label. No products met the acceptance criteria of the United States Pharmacopeia and International Council for Harmonisation (ICH) as well as the criteria adapted by the authors. One product had no detectable artemisinin, and the other three products were much higher than the stated label strength. The results of this study reinforce the importance of testing unapproved and unregulated supplements before recommending a supplement for clinical use in dogs.

Indexed as

ArtemisininsDietary SupplementsAnimalsChromatography, High Pressure LiquidDog DiseasesDogsUnited StatesartemisininArtemisininsArtemisininBabesiadogsHPLCsupplement

Identifiers

PMID39180470
PMCPMC11704989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.